

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
 Estimated average burden
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Almstead Neil Gregory</u> <hr/> (Last) (First) (Middle) <u>C/O PTC THERAPEUTICS, INC.</u> <u>100 CORPORATE COURT</u> <hr/> (Street) <u>SOUTH</u> NJ <u>07080</u> <u>PLAINFIELD</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/19/2013</u>	3. Issuer Name and Ticker or Trading Symbol <u>PTC THERAPEUTICS, INC. [PTCT]</u> <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Senior VP, Research and CMC</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	40,740	D	
Common Stock	1,549	I	By spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	05/15/2023	Common Stock	15,000	10.85	D	
Stock Option (right to buy)	(2)	05/15/2023	Common Stock	95,000	10.85	D	
Stock Option (right to buy)	(3)	05/15/2023	Common Stock	600	10.85	I	By spouse
Stock Option (right to buy)	(4)	01/10/2022	Common Stock	166	218.4	D	
Stock Option (right to buy)	(5)	01/10/2022	Common Stock	7	218.4	I	By spouse
Stock Option (right to buy)	(6)	04/27/2021	Common Stock	216	490.8	D	
Stock Option (right to buy)	(7)	04/27/2021	Common Stock	7	490.8	I	By spouse
Stock Option (right to buy)	(8)	02/02/2020	Common Stock	200	1,149.6	D	
Stock Option (right to buy)	(9)	02/02/2020	Common Stock	1	1,149.6	I	By spouse
Stock Option (right to buy)	(10)	10/07/2019	Common Stock	12	508.8	I	By spouse
Stock Option (right to buy)	(11)	05/15/2019	Common Stock	200	451.2	D	
Stock Option (right to buy)	(11)	04/01/2018	Common Stock	194	735.6	D	
Stock Option (right to buy)	(11)	01/25/2018	Common Stock	166	735.6	D	
Stock Option (right to buy)	(11)	04/18/2017	Common Stock	137	626.4	D	
Stock Option (right to buy)	(11)	03/01/2016	Common Stock	119	392.4	D	
Stock Option (right to buy)	(11)	05/24/2015	Common Stock	106	226.8	D	
Stock Option (right to buy)	(11)	11/05/2014	Common Stock	640	226.8	D	

Explanation of Responses:

1. This option was granted on May 15, 2013 and vests over four years, subject to achievement of specified performance objectives, with 25% of the shares underlying the option vesting on December 31, 2013 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on January 31, 2014.
2. This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vesting on May 15, 2014 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter beginning on June 30, 2014.
3. This option was granted on May 15, 2013 and vests over two years, with 50% of the shares underlying the option vesting on May 15, 2014 and the remaining 50% of the original number of shares underlying the option vesting on May 15, 2015.
4. This option was granted on January 10, 2012 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2013 and an additional 6.25% of the original number of shares

underlying the option vesting quarterly thereafter beginning on April 1, 2013.

5. This option was granted on January 10, 2012 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2013 and an additional 6.25% of the original number of shares underlying the option vesting quarterly thereafter beginning on April 1, 2013.

6. This option was granted on April 27, 2011 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2012 and an additional 6.25% of the original number of shares underlying the option vesting quarterly thereafter beginning on April 1, 2012.

7. This option was granted on April 27, 2011 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2012 and an additional 6.25% of the original number of shares underlying the option vesting quarterly thereafter beginning on April 1, 2012.

8. This option was granted on February 2, 2010 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2011 and an additional 6.25% of the original number of shares underlying the option vesting quarterly thereafter beginning on April 1, 2011.

9. This option was granted on February 2, 2010 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2011 and an additional 6.25% of the original number of shares underlying the option vesting quarterly thereafter beginning on April 1, 2011.

10. This option was granted on October 7, 2009 and vests over four years, with 25% of the shares underlying the option vesting on October 1, 2010 and an additional 25% of the original number of shares underlying the option vesting at the end of each successive twelve-month period thereafter.

11. Currently exercisable.

Remarks:

Exhibit Index: 24.1 Power of Attorney

/s/ Neil Gregory Almstead 06/19/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Limited Power Of Attorney For Section 16 Reporting Obligations

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Shane Kovacs, Mark E. Boulding, Donald Mankoff, and Kurt Andrews, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of, and/or holder of equity in, PTC Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering Analysis and Retrieval System of the SEC;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this June 19, 2013.

/s/ Neil Gregory Almstead

Signature

Name: Neil Gregory Almstead